Welcome to YHEC’s publication hub

Our latest research, all in one place. Browse our collection of journal articles, reports and conference proceedings to see how we’re contributing to HEOR research. Remember to: 

  • Filter by service, therapeutic area, or geography to narrow your results.
  • Search directly for keywords or specific titles to find what you need instantly.
Conference proceeding

Can a Diagnostic AI Tool to Read Prostate Cancer Biopsies Benefit the NHS?

YHEC authors: Angel Varghese, Sam Woods
Publication date: February 2025
Conference: NHS and RCR Global AI Conference, London
Type of conference proceeding: Poster
Peer-reviewed publication

Host-Response Testing with MeMed BV in Community-Acquired Pneumonia: An Economic Evaluation from the UK NHS Perspective

YHEC authors: Emily Gregg, Sara Graziadio, William Green, Daniela Afonso, Monica Garrett, Karina Watts, Deborah Watkins
Publication date: February 2025
Journal: JAC-Antimicrobial Resistance

Abstract

BACKGROUND: Community-acquired pneumonia (CAP) remains a leading cause of hospital admissions and mortality. A novel host-response test, MeMed BV (MMBV), has been developed for discriminating between bacterial and viral infection that could improve the clinical management of CAP.

OBJECTIVES: To evaluate the cost-effectiveness of using MMBV to guide antibiotic decisions in the clinical management of CAP in the UK.

METHODS: An economic model was developed to understand the incremental cost per person associated with the implementation of MMBV from the UK NHS perspective. A qualitative care pathway analysis was performed to inform the standard of care (SOC) and SOC plus MMBV (SOC + MMBV) clinical pathways captured in the model.

RESULTS: In the base case analysis, the SOC + MMBV strategy for a hypothetical cohort of 1000 patients (adults and children modelled independently) presenting to the emergency department with suspected CAP was estimated to provide total cost savings of £134 018 and £105 750 for adults and children, respectively. Cost savings were associated with reductions in total antibiotic treatment, the number of patients receiving additional diagnostic tests, and hospital admissions. Deterministic sensitivity analysis revealed that the specificity of SOC + MMBV and sensitivity of the SOC were primary drivers of the cost model for adults, whereas the specificity of SOC and SOC + MMBV were primary drivers for paediatrics.

CONCLUSIONS: Overall, the model predicts that the introduction of SOC + MMBV has the potential to be cost-saving and promote antimicrobial stewardship for both adult and paediatric CAP patients.

Conference proceeding

What is the Economic Value of an AI Tool for the Triage of Skin Cancer in the UK?

YHEC authors: Angel Varghese, Sam Woods
Publication date: February 2025
Conference: NHS and RCR Global AI Conference, London
Type of conference proceeding: Poster
Peer-reviewed publication

A Systematic Review of Bone Graft Products Used in Lumbar Interbody Fusion Procedures for Degenerative Disc Disease

YHEC authors: Anita Fitzgerald, Rachael McCool, Emma Carr, Paul Miller, Katie Reddish
Publication date: January 2025
Journal: North American Spine Society Journal (NASSJ)

Abstract

BACKGROUND: Degenerative disc disease (DDD) is associated with chronic lower back pain that may have impacts on individual's quality of life and functional ability. Lumbar interbody fusion can be carried out with a variety of bone grafting products, the choice depends on several factors including the patient, site, procedure, cost and indication. This systematic review (SR) intends to validate and consolidate the existing evidence base supporting bone graft materials related to lumbar interbody fusion procedures for DDD, specifically anterior lumbar interbody fusion (ALIF) and oblique lumbar interbody fusion (OLIF).

METHODS: An SR was conducted in February 2023. Clinical and economic studies of adults with DDD in regions L2 to S1 undergoing lumbar interbody fusion with Infuse™, allograft, synthetic bone grafts, demineralized bone matrices or cell-based matrices were eligible for inclusion.

RESULTS: Twenty-one studies (reported in 25 publications) were included in the review. Eighteen studies (reported in 22 publications) reported clinical outcomes, while 4 studies reported economic outcomes. Nine studies (in 5 publications) investigated Infuse™, including 3 randomized controlled trials (RCTs), one cohort study and 4 case series. Ten studies investigated allograft bone, bone harvested from the vertebral spur combined with apacerum powder, or tricalcium phosphate soaked in autologous bone marrow aspirate, including one RCT, 2 cohort studies, and 7 case series.

CONCLUSIONS: The SR shows that Infuse™ offers comparable results to iliac crest bone graft with the benefit of not requiring harvested bone and offers significant benefits in surgical time and blood loss. There is a lack of comparative evidence for any other bone grafts identified in this SR, highlighting the need for further well-designed studies to be conducted in this area.

Peer-reviewed publication

Single-Arm Interventional versus Observational Studies for Assessing Efficacy: A Meta-Epidemiological Study

YHEC authors: Mary Chappell, Deborah Watkins, Alice Sanderson, Lavinia Ferrante di Ruffano, Paul Miller, Hariet Fewster, Anita Fitzgerald, Mary Edwards, Rachael McCool
Publication date: January 2025
Journal: Cochrane Evidence Synthesis and Methods

Abstract

INTRODUCTION: Interventional single-arm trials (SATs) are increasingly being used as evidence, despite a lack of agreement on their validity and where they should sit in the hierarchy of evidence. We conducted a meta-epidemiological study to investigate whether there are systematic differences in outcomes and levels of between-study heterogeneity for SATs compared with their observational counterpart, single-arm cohort studies.

METHODS: We identified systematic reviews (SRs) of pharmacological interventions, published in 2023, that included both interventional and observational single-arm studies. For each SR, subgroup meta-analysis of dichotomous outcomes was conducted for included SATs and single-arm cohort studies to assess effect sizes, levels of heterogeneity and between group differences. In a sensitivity analysis, clinically heterogeneous primary studies were removed and analyses re-run.

RESULTS: 66 SRs contained single-arm studies, of which 13 reported meta-analyses of dichotomous efficacy outcomes. There was no overall risk difference for SATs compared with single-arm cohort studies (risk difference: -0.020, 95% CI: -0.092 to 0.052, p = 0.59). In the sensitivity analysis, there was a tendency to higher effect for single-arm cohort studies, but no significant difference (risk difference: -0.071, 95% CI: -0.161, 0.019, p = 0.12). There were high levels of between-study heterogeneity within both SATs (median; range I2: 54.8; 11.3-91.0) and single-arm cohorts (median; range I2: 77.2; 0-94.7) and heterogeneity remained high in the sensitivity analysis.

CONCLUSION: There do not appear to be systematic differences in outcome between SATs and single-arm cohort studies, but further research is recommended to confirm this finding. Levels of heterogeneity are high within both designs, even after attempts to reduce clinical heterogeneity. Because clinical heterogeneity had potentially been removed, remaining statistical heterogeneity may have been due to bias related to study conduct. Future work should utilize larger samples and additional methods to further clarify the relative validity of single-arm designs.

Conference proceeding

Clinical and Economic Impact of Long-Term Disease Modifying Transfusions in Adults as a Prophylactic Intervention for Sickle Cell Disease Crises

YHEC authors: Sarah Medland, Jamie Bainbridge, Stuart Mealing
Publication date: December 2024
Conference: American Society of Hematology Annual Meeting & Exposition, San Diego
Type of conference proceeding: Poster

Abstract

BACKGROUND: In 2021, there were an estimated 7.74 million people living with sickle cell disease (SCD) globally: a 41% increase from 2001 (Thomson et al. The Lancet Haematology, 2023). Regular automated red blood cell exchange (aRBCX) has been shown to improve control and management of SCD compared with manual red blood cell exchange (mRBCX) (Tsitsikas et al. Journal of Clinical Medicine, 2021). This study compared the expected clinical event frequency and economic impact of aRBCX with mRBCX in adults with SCD requiring regular disease-modifying transfusion treatments (DMTs). The study focussed on adults at high risk of clinical events and ineligible for, refractory to, or unwilling to take disease-modifying pharmacological treatments (e.g. hydroxyurea).

METHODS: A global individual patient-level simulation model was developed to estimate lifetime clinical events and costs of a heterogenous population of adults with SCD (aged over 18) requiring regular DMTs. A UK perspective was used in the base case. Adults received a DMT per cycle as per local recommendations. Monte Carlo methods were employed to determine the presence of iron overload at baseline and after mRBCX. Chelation therapy treats iron overload. Monte Carlo methods determined clinical event occurrence. Clinical events are not mutually exclusive in practice. Thus, an adult's clinical event history, in particular vaso-occlusive crises (VOCs), impacted subsequent clinical event and mortality rates. Clinical events impacted costs and health-related quality of life (HRQoL).

Findings from a pragmatic review informed efficacy, mortality, HRQoL and cost parameters. Where data were sparce, clinical experts were consulted to inform inputs and assumptions. Costs were sourced from national databases and literature and were inflated to 2022/23 if necessary. Costs and HRQoL were discounted in line with local guidelines. 250 lifetime simulations of 250 adults were run, with parameters varied probabilistically on their statistical distribution when appropriate.

RESULTS: The total number of lifetime acute clinical events reduced by 18% with aRBCX compared with mRBCX. VOC reduction comprised 96% of the total acute clinical event change. The total number of lifetime VOCs reduced from 66.04 (64.7 to 67.39) with mRBCX to 52.86 (51.25 to 54.47) with aRBCX.

aRBCX is more resource intensive and costly per administration than mRBCX. However, aRBCX required 49% fewer DMT administrations than mRBCX (43% fewer when considering DMTs and emergency transfusions). Adults receiving mRBCX spent on average 41.93 (41.09 to 42.76) months (14% of their adult life) on chelation therapy compared with 5.45 (5.43 to 5.48) months for those receiving aRBCX with iron overload at baseline.
Over a lifetime, aRBCX was expected to save £52,097 (£49,957 to £54,238) per person compared with mRBCX. Key drivers of this cost saving were the reduction in VOCs, DMTs and time on chelation therapy. aRBCX was cost saving compared with mRBCX in 99% of the probabilistic model runs.

DISCUSSION: aRBCX allows for increased success in achieving clinical targets, leading to improved control of SCD, fewer transfusions, fewer clinical events, and less time on chelation therapy. There is potential for large cost savings, allowing funds, hospital beds, and staff time to be redistributed.
The global model can be adapted to other healthcare settings where SCD prevalence and mortality are high. Research into the life-altering and cost-saving potential of aRBCX in these settings is essential to achieve the World Health Organisation's (WHO) goal of achieving universal health coverage by integrating SCD treatments into existing healthcare programmes in an equitable and cost-effective manner (WHO, Sickle strategic guidance framework, 2024).

Conference proceeding

Clinical and Economic Impact of Long-Term Disease Modifying Transfusions in Paediatrics as a Prophylactic Intervention for Sickle Cell Disease Crises

YHEC authors: Sarah Medland, Jamie Bainbridge, Stuart Mealing
Publication date: December 2024
Conference: American Society of Hematology Annual Meeting & Exposition, San Diego
Type of conference proceeding: Poster

Abstract

BACKGROUND: Sickle cell disease (SCD) and all associated comorbidities were estimated to be the 12th most common cause of mortality in children younger than 5 years in 2021 (Thomson et al. The Lancet Haematology, 2023). Regular automated red blood cell exchange (aRBCX) improves management of SCD compared with manual red blood cell exchange (mRBCX) (Tsitsikas et al. Journal of Clinical Medicine, 2021). This study compared the expected clinical event frequency and economic impact of aRBCX with mRBCX in children with SCD requiring regular disease modifying transfusion treatments (DMTs). The study focussed on children at high risk of clinical events and ineligible for, refractory to, or unwilling to take disease modifying pharmacological treatments (e.g. hydroxyurea).

METHODS: A global individual patient-level simulation model was developed to estimate lifetime clinical events and costs of regular aRBCX compared with mRBCX in a heterogenous population of children aged 2 with no history of chronic events. The UK cost perspective was investigated. People received a DMT per cycle as per local recommendations. Monte Carlo methods determined the presence of iron overload. Chelation therapy treats iron overload. Monte Carlo methods determined clinical event occurrence. Clinical events are not mutually exclusive in practice. Thus, a person's clinical event history, in particular vaso-occlusive crises (VOCs), impacted subsequent clinical event and mortality rates. Clinical events impacted costs and health-related quality of life (HRQoL).

Findings from a pragmatic review informed efficacy, mortality, HRQoL and cost parameters. Where data were sparce, clinical experts were consulted to inform inputs and assumptions. Costs were sourced from national databases and literature and inflated to 2022/23 if necessary. Costs and HRQoL were discounted in line with local guidelines. A preliminary model run with 250 lifetime simulations of 250 children varied parameters probabilistically on their statistical distribution when appropriate.

RESULTS: Total acute clinical events were 19% lower with aRBCX compared with mRBCX. VOCs reduced by 20% from 117 (115 to 119) for mRBCX to 94 (91 to 96) for aRBCX. aRBCX also caused a reduction of 9% for ACS and 2% for strokes.
aRBCX is more resource intensive and costly per administration than mRBCX, but, aRBCX required 49% fewer DMT administrations than mRBCX (44% fewer when considering DMTs and emergency transfusions). People receiving mRBCX were anticipated to spend approximately 13% of their life on chelation therapy, totalling 6.4 (6.3 to 6.5) years. Only people with iron overload at baseline had chelation therapy with aRBCX, totalling 5.5 (5.4 to 5.5) months.

aRBCX was cost saving compared to mRBCX. Regular aRBCX was expected to save £109,964 (£107,275 to £112,653) per lifetime compared with mRBCX. This conclusion was consistent for 100% of the 250 probabilistic model runs and for scenarios where children received DMTs until adulthood and the lifetime of children at high risk of stroke.

DISCUSSION: aRBCX allows for increased success in achieving clinical targets leading to improved control of SCD, fewer transfusions, clinical events and time on chelation therapy. There is potential for large cost savings, allowing funds, hospital beds, and staff time to be redistributed.
The global model can be easily adapted to other healthcare settings where SCD prevalence and mortality are high. Research into the life-altering and cost-saving potential of aRBCX in these settings is essential to achieve the World Health Organisation's (WHO) goal of achieving universal health coverage by integrating SCD treatments into existing healthcare programmes in an equitable and cost-effective manner (WHO, Sickle strategic guidance framework, 2024).

1 … 9 10 11 12 13 … 83